HIV/AIDS Topics CROI 2011: Safety and Acceptability of Tenofovir Gel and Tablets for Pre-exposure Prevention
- Details
- Category: HIV Prevention
- Published on Friday, 04 March 2011 00:00
- Written by Paul Dalton
A vaginal microbicide gel containing 1% tenofovir (Viread) was found to be generally well tolerated and acceptable by American and African women, though some study participants preferred taking a pill for HIV pre-exposure prophylaxis (PrEP), according to study findings reported this week at the 18th Conference on Retroviruses and Opportunistic Infections (CROI 2011) in Boston. A related study found that the vaginal gel was not optimal for rectal use, and researchers are working on a more suitable formulation.
CROI 2011: Safety and Acceptability of Tenofovir Gel and Tablets for Pre-exposure Prevention
- Details
- Category: HIV Prevention
- Published on Friday, 04 March 2011 00:00
- Written by Paul Dalton
A vaginal microbicide gel containing tenofovir was found to be generally well tolerated and acceptable by American and African women, though some study participants preferred taking a pill for HIV pre-exposure prophylaxis (PrEP), according to study findings reported this week at the 18th Conference on Retroviruses and Opportunistic Infections (CROI 2011) in Boston. A related study found that the vaginal gel was not suitable for rectal use, and researchers are working on a more tolerable formulation.
U.S. Advocates Offer Strategies for Pre-exposure Prophylaxis to Prevent HIV Infection
- Details
- Category: HIV Prevention
- Published on Tuesday, 14 December 2010 20:32
- Written by Liz Highleyman
The National PrEP Committee, a new coalition of treatment advocates, policy experts, and others, has released a report on strategies for using pre-exposure prophylaxis, or taking antiretroviral drugs as a way to prevent HIV infection. Recently published data from the iPrEx trial showed that daily use of tenofovir/emtricitabine (Truvada) reduced the risk of HIV acquisition by 44% among gay and bisexual men, but many questions remain regarding adherence, cost, and other potential concerns.
CDC Issues Guidance for Truvada Pre-exposure Prophylaxis
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Tuesday, 01 February 2011 00:00
- Written by Liz Highleyman
The U.S. Centers for Disease Control and Prevention (CDC) this week issued interim guidance regarding the use of tenofovir/emtricitabine (Truvada) for pre-exposure prophylaxis (PrEP) against HIV infection. The guidelines, published in the January 28, 2011, Morbidity and Mortality Weekly Report, note the limitations of the recent iPrEx trial and recommend PrEP only for gay/bisexual men with "substantial, ongoing, high risk" for acquiring HIV.
Truvada PrEP Cuts HIV Infection by 44% among Gay/Bisexual Men in Worldwide Study
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Monday, 22 November 2010 21:13
- Written by Liz Highleyman
Pre-exposure prophylaxis (PrEP) using a daily combination of tenofovir and emtricitabine (the drugs in the Truvada coformulation) reduced the risk of acquiring HIV by 44%, according to a large international study of men who have sex with men. As described in the November 23, 2010 advance online edition of the New England Journal of Medicine, the iPrEx study found that men who achieved good adherence had more than a 70% reduction in new infections. The drug combo was well-tolerated over nearly 3 years of follow-up, with mostly mild, transient side effects.
More Articles...
- Black Men Who Have Sex with Men Have Higher HIV Rate despite Less Sexual Risk Behavior
- FDA Grants Fast-track Status for Tenofovir Microbicide Gel for HIV Prevention
- Non-stick Coating Added to Semen Protein May Help Reduce HIV Infection
- U.S. Conference on AIDS Calls for Community Mobilization to Improve HIV Prevention, Testing, and Care
Web Design and Development by